CD19 and T-cell acute lymphoblastic leukemia: In the context of CAR-T therapies, VHH-based CD7-redirected CAR-Ts (NCT04004637) and CD19/CD20-redirected CAR-Ts (NCT03881761) have entered clinical trials to be assessed for the treatment of certain patients T-cell ALL (T-ALL) and B-cell lymphoma, respectively [14].